Crinetics Pharmaceuticals has secured FDA approval for Palsonify (paltusotine), the first once-daily oral therapy for acromegaly patients who are either ineligible for surgery or have inadequately responded to it. This rare endocrine disorder is characterized by excessive growth hormone production. The approval positions Crinetics to compete directly against established injectable therapies from Novartis and Ipsen, potentially reshaping the treatment landscape. Clinical trials demonstrated significant reductions in growth hormone levels with a favorable safety profile. CEO Scott Struthers emphasized the milestone’s significance for patients and the company alike.